Usefulness of bezafibrate for ovulation induction in clomiphene citrate-resistant polycystic ovary syndrome patients with dyslipidemia: A prospective pilot study of seven cases

Gynecologic and Obstetric Investigation

Volumn 70, Issue 3, 2010, Pages 166-172

  Hara, Shuichiro ^a   Takahashi, Toshifumi ^a   Amita, Mitsuyoshi ^a   Igarashi, Hideki ^a   Kurachi, Hirohisa ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Bezafibrate; Clomiphene citrate resistance; Dyslipidemia; Insulin resistance; Polycystic ovary syndrome

Indexed keywords

BEZAFIBRATE; CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE;

ADULT; ARTICLE; ARTIFICIAL INSEMINATION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; FEMALE INFERTILITY; HORMONE RESISTANCE; HUMAN; MENSTRUATION; OVARY FOLLICLE; OVARY FOLLICLE MATURATION; OVARY POLYCYSTIC DISEASE; OVULATION; OVULATION INDUCTION; PILOT STUDY; PREGNANCY OUTCOME; PRIORITY JOURNAL; TRANSVAGINAL ECHOGRAPHY; TREATMENT OUTCOME;

ADULT; BEZAFIBRATE; CLOMIPHENE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; FERTILITY AGENTS, FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; INFERTILITY, FEMALE; OVULATION INDUCTION; PILOT PROJECTS; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY RATE; PROSPECTIVE STUDIES;

EID: 77953606706     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000316265     Document Type: Article

References (60)

1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R: Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078-3082.
2. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI: A survey of the polycystic ovary syndrome in the greek island of lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999; 84: 4006-4011.
3. Asuncion M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF: A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85: 2434-2438.
4. Ehrmann DA: Polycystic ovary syndrome. N Engl J Med 2005; 352: 1223-1236.
5. Homburg R: Clomiphene citrate - end of an era? A mini-review. Hum Reprod 2005; 20: 2043-2051.
6. Hughes E, Collins J, Vandekerckhove P: Clomiphene citrate for ovulation induction in women with oligo-amenorrhoea. Cochrane Database Syst Rev 2000:CD000056.
7. Kim LH, Taylor AE, Barbieri RL: Insulin sensitizers and polycystic ovary syndrome: can a diabetes medication treat infertility? Fertil Steril 2000; 73: 1097-1098.
8. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008; 89: 505-522.
9. Bremer AA, Miller WL: The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia and insulin resistance. Fertil Steril 2008; 89: 1039-1048.
10. Dunaif A: Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800.
11. Adashi EY, Resnick CE, D'Ercole AJ, Svoboda ME, Van Wyk JJ: Insulin-like growth factors as intraovarian regulators of granulosa cell growth and function. Endocr Rev 1985; 6: 400-420.
12. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG: A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991; 72: 83-89.
13. Franks S, Gilling-Smith C, Watson H, Willis D: Insulin action in the normal and polycystic ovary. Endocrinol Metab Clin North Am 1999; 28: 361-378.
14. Glueck CJ, Moreira A, Goldenberg N, Sieve L, Wang P: Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod 2003; 18: 1618-1625.
15. Lord JM, Flight IH, Norman RJ: Metformin in polycystic ovary syndrome: Systematic review and meta-analysis. BMJ 2003; 327: 951-953.
16. Ota H, Goto T, Yoshioka T, Ohyama N: Successful pregnancies treated with pioglitazone in infertile patients with polycystic ovary syndrome. Fertil Steril 2008; 90: 709-713.
17. Sepilian V, Nagamani M: Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metab 2005; 90: 60-65. (Pubitemid 40116634)
18. Teede HJ, Hutchison S, Zoungas S, Meyer C: Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS. Endocrine 2006; 30: 45-53.
19. Cussons AJ, Stuckey BG, Watts GF: Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis 2006; 185: 227-239.
20. Legro RS: Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 2003; 24: 302-312.
21. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.
22. Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA: Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab 2005; 90: 2545-2549.
23. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE: Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 1929-1935.
24. Rizzo M, Berneis K, Carmina E, Rini GB: How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome? Am J Obstet Gynecol 2008; 198: 28.
25. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088-2093.
26. Tenenbaum A, Fisman EZ, Boyko V, Benderly M, Tanne D, Haim M, Matas Z, Motro M, Behar S: Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med 2006; 166: 737-741.
27. Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S: Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 2004; 109: 2197-2202.
28. Taniguchi A, Fukushima M, Sakai M, Tokuyama K, Nagata I, Fukunaga A, Kishimoto H, Doi K, Yamashita Y, Matsuura T, Kitatani N, Okumura T, Nagasaka S, Nakaishi S, Nakai Y: Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients. Metabolism 2001; 50: 477-480.
29. Tenenbaum A, Motro M, Fisman EZ, Adler Y, Shemesh J, Tanne D, Leor J, Boyko V, Schwammenthal E, Behar S: Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J 2005; 26: 2032-2038.
30. Mizunuma H, Irahara M, Committee for Reproductive and Endocrine in Japan: Society of Obstetrics and Gynecology. Annual report for the determination of diagnostic criteria for polycystic ovary syndrome. Acta Obstet Gynaecol Jpn 2007; 59: 1142-1147.
31. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M: Diagnostic criteria for dyslipidemia: executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular dis - eases for Japanese. J Atheroscler Thromb 2007; 14: 155-158.
32. World Health Organization: Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interaction, ed 4. Cambridge, Cambridge University Press, 1999.
33. Baba T, Endo T, Sata F, Honnma H, Kitajima Y, Hayashi T, Manase K, Kanaya M, Yamada H, Minakami H, Kishi R, Saito T: Polycystic ovary syndrome is associated with genetic polymorphism in the insulin signaling gene IRS-1 but not ENPP1 in a Japanese population. Life Sci 2007; 81: 850-854.
34. Kurabayashi T, Suzuki M, Fujita K, Murakawa H, Hasegawa I, Tanaka K: Prognostic factors for ovulatory response with clomiphene citrate in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2006; 126: 201-205.
35. Murakawa H, Hasegawa I, Kurabayashi T, Tanaka K: Polycystic ovary syndrome: insulin resistance and ovulatory responses to clomiphene citrate. J Reprod Med 1999; 44: 23-27.
36. Ma F, Qiao L, Yue H, Xie S, Zhou X, Jiang M, Zhang W, Qi J, Wang L, Xu K: Homeostasis model assessment-insulin resistance (HOMA-ir), a key role for assessing the ovulation function in polycystic ovary syndrome (PCOS) patients with insulin resistance. Endocr J 2008; 55: 943-945.
37. Espinosa de los Monteros A, Ayala J, Sanabria LC, Parra A: Serum insulin in clomiphene responders and nonresponders with polycystic ovarian disease. Rev Invest Clin 1995; 47: 347-353.
38. Trolle B, Flyvbjerg A, Kesmodel U, Lauszus FF: Efficacy of metformin in obese and nonobese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. Hum Reprod 2007; 22: 2967-2973.
39. Moran LJ, Noakes M, Clifton PM, Tomlinson L, Galletly C, Norman RJ: Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 812-819.
40. Stamets K, Taylor DS, Kunselman A, Demers LM, Pelkman CL, Legro RS: A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil Steril 2004; 81: 630-637.
41. Moran LJ, Brinkworth G, Noakes M, Norman RJ: Effects of lifestyle modification in polycystic ovarian syndrome. Reprod Biomed Online 2006; 12: 569-578. (Pubitemid 43674928)
42. Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH: Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome: a randomized, placebo-controlled, double-blind multicentre study. Hum Reprod 2006; 21: 80-89.
43. Rouzi AA, Ardawi MS: A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. Fertil Steril 2006; 85: 428-435.
44. Ghazeeri G, Kutteh WH, Bryer-Ash M, Haas D, Ke RW: Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003; 79: 562-566.
45. Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW, Nestler JE: Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001; 75: 310-315.
46. Hwu YM, Lin SY, Huang WY, Lin MH, Lee RK: Ultra-short metformin pretreatment for clomiphene citrate-resistant polycystic ovary syndrome. Int J Gynaecol Obstet 2005; 90: 39-43.
47. Khorram O, Helliwell JP, Katz S, Bonpane CM, Jaramillo L: Two weeks of metformin improves clomiphene citrate-induced ovulation and metabolic profiles in women with polycystic ovary syndrome. Fertil Steril 2006; 85: 1448-1451.
48. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R: Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998; 338: 1876-1880.
49. Yarali H, Yildiz BO, Demirol A, Zeyneloglu HB, Yigit N, Bukulmez O, Koray Z: Co-administration of metformin during rFSH treatment in patients with clomiphene citrate- resistant polycystic ovarian syndrome: a prospective randomized trial. Hum Reprod 2002; 17: 289-294.
50. Diamanti-Kandarakis E, Papavassiliou AG: Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med 2006; 12: 324-332.
51. Attia GR, Rainey WE, Carr BR: Metformin directly inhibits androgen production in human thecal cells. Fertil Steril 2001; 76: 517-524.
52. Mansfield R, Galea R, Brincat M, Hole D, Mason H: Metformin has direct effects on human ovarian steroidogenesis. Fertil Steril 2003; 79: 956-962.
53. Mitwally MF, Witchel SF, Casper RF: Troglitazone: a possible modulator of ovarian steroidogenesis. J Soc Gynecol Investig 2002; 9: 163-167.
54. Komar CM, Braissant O, Wahli W, Curry TE Jr: Expression and localization of PPARs in the rat ovary during follicular development and the periovulatory period. Endocrinology 2001; 142: 4831-4838.
55. Goldenberg I, Benderly M, Goldbourt U: Update on the use of fibrates: focus on bezafibrate. Vasc Health Risk Manag 2008; 4: 131-141.
56. Ofori B, Rey E, Bérard A: Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol 2007; 64: 496-509.
57. Kodaman PH, Duleba AJ: HMG-CoA reductase inhibitors: do they have potential in the treatment of polycystic ovary syndrome? Drugs 2008; 68: 1771-1785.
58. Kaya C, Cengiz SD, Berker B, Demirtas S, Cesur M, Erdogan G: Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril 2009; 92: 635-642.
59. Duleba AJ, Banaszewska B, Spaczynski RZ, Pawelczyk L: Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertil Steril 2006; 85: 996-1001.
60. Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL: The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J Clin Endocrinol Metab 2009; 94: 103-108.